This Medudy course is a video tutorial for physicians on the topic “From Biopsy to Biomarker: Quality Assurance in Predictive Diagnostics for Advanced Gastric Cancer.”
In this video, Prof. Dr. Sylvie Lorenzen, a senior physician at the Department of Internal Medicine III at the Klinikum rechts der Isar of the Technical University of Munich, whose clinical focus is on gastrointestinal tumors, traces the path from endoscopic biopsy to a valid biomarker result and explains why diagnostic quality assurance for gastric cancer is an interdisciplinary task.
The focus is on the guideline-based requirements for biopsy—including the number of samples, representativeness, and the significance of intratumoral heterogeneity for HER2 testing. Using the example of mismatch repair and MSI diagnostics, the requirements for interpreting results are illustrated, including the CAP/ASCO recommendations on testing methodology (IHC and PCR), the handling of discordant or indeterminate results, and the distinction from next-generation sequencing panels.
Finally, the interdisciplinary diagnostic workflow linking endoscopy, pathology, and the tumor board is presented—as the basis for quality-assured, biomarker-guided treatment decisions.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
This course was made possible with the generous support of MSD.
By the end of this course, you will know:
- Guideline-based requirements for biopsy in gastric cancer
- The four predictive biomarkers and their diagnostic relevance
- the preferred testing methods for dMMR/MSI diagnostics
- the interdisciplinary workflow for quality-assured biomarker determination
